CJC-1295 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
==== Monoamine oxidase B (MAO-B) inhibitors ==== Rasagiline (Agilect; AGN-1135; Azilect; Elbrus; Lu-00-773; TV-1030; TVP-101; TVP-1012) – monoamine oxidase B (MAO-B) inhibitor [338] Safinamide (EMD-1195686; Equfina; FCE-26743; ME-2125; NW-1015; Onstryv; PNU-151774; Xadago; ZP-034) – reversible monoamine oxidase B (MAO-B) inhibitor and other actions [339] Selegiline (Eldepryl, Jumex) – monoamine oxidase B (MAO-B) inhibitor and other actions Selegiline orally disintegrating tablet (Efupi; FPF-1100-NW; selegiline ODT) – monoamine oxidase B (MAO-B) inhibitor and other actions [340]
R-NH2 + DBNPA → R-NH-C(Br)(NO2)NH2 In basic environments, DBNPA undergoes nucleophilic substitution by hydroxide ions, which initiates hydrolysis. This reaction reduces the environmental persistence of DBNPA by breaking it down into smaller degradation products.
==== 11 September attacks ==== In the months following the 9/11 attacks, Hitchens and Noam Chomsky debated the nature of radical Islam and the proper response to it in a highly charged exchange of letters in The Nation, including discussion of whether any comparison could be legitimately made between the 9/11 attacks and the 1998 Al Shifa bombing by the U.S. Approximately a year after the 9/11 attacks and his exchanges with Chomsky, Hitchens left The Nation, claiming that its editors, readers and contributors considered John Ashcroft a bigger threat than Osama bin Laden, and were making excuses on behalf of Islamist terrorism; in the following months he wrote articles increasingly at odds with his former colleagues.
Sources: en.wikipedia.org
== Personal life == Sherman met and married Hildegard Schroeder while they were both graduate students at the University of Iowa, and they had three children: Karen, Marc, and Keith. In addition to his professional activities, he has participated in organizations such as the Boy Scouts of America, the Jewish War Veterans organization, and the Lions Club. Sherman died on December 1, 2023, at the age of 98.
=== Molecular mechanism === At the molecular level, a cell senses insulin through insulin receptors, with the signal propagating through the insulin signal transduction pathway. Recent studies suggested that the pathway may operate as a bistable switch under physiologic conditions for certain types of cells, and insulin response may well be a threshold phenomenon. The pathway's sensitivity to insulin may be blunted by many factors such as lipolysis of free fatty acids, causing insulin resistance. From a broader perspective, however, sensitivity tuning (including sensitivity reduction) is a common practice for an organism to adapt to the changing environment or metabolic conditions. Pregnancy, for example, entails significant metabolic changes, during which the mother must decrease the insulin sensitivity of her muscles to conserve more glucose for both the maternal and fetal brains. This adaptation can occur by elevating the response threshold, thereby delaying the onset of sensitivity. This is achieved through the secretion of placental growth factor, which interferes with the interaction between insulin receptor substrate (IRS) and PI3K. This concept forms the basis of the adjustable threshold hypothesis of insulin resistance. Insulin resistance has been proposed to be a reaction to excess nutrition by superoxide dismutase in cell mitochondria that acts as an antioxidant defense mechanism. This link seems to exist under diverse causes of insulin resistance.
The American tea culture is a part of the history of the United States, as tea has appealed to all classes and has adapted to the customs of the United States. The Native peoples of North America drank various herbal teas, the most common of which was Yaupon tea, known as the "Beloved drink", "Cassina", or "White drink". It was brewed from yaupon holly (Ilex vomitoria), which is native to the Atlantic and Gulf Coasts. Native American tribes like the Chickasaw, Cherokee, Choctaw, Muscogee, and Timucua used the tea as a daily drink, as a social drink used in meetings, and in various rituals, many of which were associated with purification. Yaupon tea was adopted by European colonists as early as the 17th century who gave it various names like "Black drink", "Carolina Tea", "South Seas Tea", or "Indian tea".
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.